Cost‐Effectiveness of Combination Disease‐Modifying Antirheumatic Drugs Versus Tumor Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: A Pragmatic, Randomized, Multicenter Trial-论文-万方医学网

首页> > Cost‐Effectiveness of Combination Disease‐Modifying Antirheumatic Drugs Versus Tumor Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: A Pragmatic, Randomized, Multicenter Trial

Cost‐Effectiveness of Combination Disease‐Modifying Antirheumatic Drugs Versus Tumor Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: A Pragmatic, Randomized, Multicenter Trial

导出原文传递

翻译打印收藏纠错

第一作者： Anita Patel

作者： Anita Patel ^[1] ; Margaret Heslin ^[2] ; David L. Scott ^[3] ; Dominic Stringer ; Fraser Birrell ; Fowzia Ibrahim

作者单位： Anita Patel Health Economics Consulting ^[1] King’s College London ^[2] Northumbria Healthcare NHS Foundation Trust, North Shields, and Newcastle University ^[3]

发布时间 2022-05-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Cost‐Effectiveness of Combination Disease‐Modifying Antirheumatic Drugs Versus Tumor Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: A Pragmatic, Randomized, Multicenter Trial

相似文献

同项目论文

相关期刊

检索历史 清除

Cost‐Effectiveness of Combination Disease‐Modifying Antirheumatic Drugs Versus Tumor Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: A Pragmatic, Randomized, Multicenter Trial

相似文献

同项目论文

相关期刊

检索历史清除